These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 3774198)

  • 21. [Interleukin 3 (IL-3) in diagnosis and monitoring of non-small-cell lung cancer].
    Mroczko B; Szmitkowski M; Czygier M
    Przegl Lek; 1999; 56(12):763-6. PubMed ID: 10789186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Bronchial carcinoma (lung cancer)].
    Häussinger K; Huber RM
    Pneumologie; 1996 Sep; 50 Suppl 2():599-603. PubMed ID: 9157424
    [No Abstract]   [Full Text] [Related]  

  • 23. Serum ferritin levels in lung cancer patients.
    Ferrigno D; Buccheri G
    Eur J Cancer; 1992; 28(1):241. PubMed ID: 1567668
    [No Abstract]   [Full Text] [Related]  

  • 24. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
    Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
    Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Panel report. Diagnosis, staging, and criteria of response to therapy for lung cancer.
    Carr DT
    Cancer Chemother Rep 3; 1973 Mar; 4(2):303-5. PubMed ID: 4580858
    [No Abstract]   [Full Text] [Related]  

  • 26. Carcinoembryonic antigen and ferritin in patients with lung cancer before and during therapy.
    Gropp C; Havemann K; Lehmann FG
    Cancer; 1978 Dec; 42(6):2802-8. PubMed ID: 728875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Tumor-associated antigens in bronchial cancer].
    Gropp C
    Fortschr Med; 1982 Jun; 100(23):1100-7. PubMed ID: 6286437
    [No Abstract]   [Full Text] [Related]  

  • 28. [Tumor markers in bronchial carcinoma. Parameters for early diagnosis, staging and treatment follow-up].
    Gropp C; Luster W
    Ric Clin Lab; 1984; 14 Suppl 2():21-31. PubMed ID: 6099605
    [No Abstract]   [Full Text] [Related]  

  • 29. How to deal with bronchogenic carcinoma in the elderly.
    Ross WM
    Geriatrics; 1976 Jun; 31(6):107-10. PubMed ID: 58805
    [No Abstract]   [Full Text] [Related]  

  • 30. [Blood tumor markers in patients with lung cancer].
    Bianco A; Marcatili P; D'Auria D; Sorrentino P; Zofra S
    Ann Ital Med Int; 1996; 11(2):114-8. PubMed ID: 8974436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of the prognostic significance of cytosolic determination of CA 125 tumor-associated antigen, carcinoembryonic antigen and squamous cell carcinoma antigen in patients with nonsmall cell lung carcinoma.
    Picardo AL; Diez M; Torres A; Maestro M; Ortega D; Hernando F; Gómez A; Garcia-Asenjo J; Balibrea JL
    Cancer; 1996 Mar; 77(6):1066-72. PubMed ID: 8635125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carcinoembryonic antigen, ferritin, anionic glycoproteins, and their sialic acid content in advanced colorectal cancer.
    Cunietti E; Locatelli E; Vaiani G; Gandini R; Gandini MC; Reggiani A; Monti M
    Cancer Detect Prev; 1985; 8(1-2):227-32. PubMed ID: 4064042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
    Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Importance of serum TPA determination in bronchopulmonary cancer. A comparative study of CEA, CA 19.9 and NSE].
    Prévost A; Passemard F; Perdu D; Vallerand H; Deschamps F; Lavaud F; Larbre H
    Rev Mal Respir; 1994; 11(4):379-84. PubMed ID: 7973038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
    Ebert W; Hoppe M; Muley T; Drings P
    Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequential photodynamic therapy (PDT) and high dose brachytherapy for endobronchial tumour control in patients with limited bronchogenic carcinoma.
    Freitag L; Ernst A; Thomas M; Prenzel R; Wahlers B; Macha HN
    Thorax; 2004 Sep; 59(9):790-3. PubMed ID: 15333857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The sensitivity and specificity of tumor markers (CEA, ferritin, beta 2-MG, TPA, IAP, sialic acid) in malignant and non-malignant pulmonary diseases and their relation to smoking and sex].
    Reshad K; Suzuki K; Inui K; Takahashi Y; Umemiya M; Nakano Y; Sakamoto M; Takeuchi Y; Shimada T
    Nihon Kyobu Shikkan Gakkai Zasshi; 1985 Nov; 23(11):1343-50. PubMed ID: 3912573
    [No Abstract]   [Full Text] [Related]  

  • 38. [What value should be given to assays of serum ferritin in breast cancers? Correlation with various biological parameters].
    Dalifard I; Daver A; Cellier P; Larra F
    Sem Hop; 1984 Jan; 60(3):157-62. PubMed ID: 6320439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.
    Okada M; Nishio W; Sakamoto T; Uchino K; Yuki T; Nakagawa A; Tsubota N
    Ann Thorac Surg; 2004 Sep; 78(3):1004-9; discussion 1009-10. PubMed ID: 15337038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The measurement of SCC antigen in squamous cell carcinoma of the lung].
    Masuoka T; Matueda Y; Ookawa H; Watanabe K; Mimoto S
    Gan No Rinsho; 1985 Jul; 31(8):914-8. PubMed ID: 4032769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.